Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the global biotech leader in rare diseases. In November 2015, you were appointed general manager Shire for Mexico, Central America & Caribbean, after a long-standing experience in large-scale multinational pharmaceutical companies. What have been your main first impressions since you took over the helm of the Mexican affiliate?
"Shire’s fundamental mission is to support and change the lives of an increasing number of patients affected by rare diseases. In this regard, Mexico clearly emerges as a country with substantial, untapped opportunities"